Reducing Nonadherence and Rehospitalization through Effective Tardive Dyskinesia Treatment
Tracking # 20-1396782
Free
There are no ratings for this course
Start courseCourse overview
Tardive dyskinesia (TD) remains an underrecognized and undertreated movement disorder that can significantly affect patients' quality of life, treatment adherence, and long-term outcomes. This interactive, case-based educational program is designed to equip managed care pharmacists, physicians, nurse practitioners, physician assistants, and other clinicians with the knowledge and practical skills needed to identify, assess, and manage TD using current evidence and guideline-based recommendations. Through expert faculty discussions, AI-enhanced patient avatars portraying realistic clinical scenarios based on authentic patient cases, an interactive mock Pharmacy & Therapeutics (P&T) Committee exercise, and live Q&A, learners will explore best practices for screening and diagnosis, differentiate TD from other drug-induced movement disorders, evaluate evidence supporting FDA-approved treatment options, and examine the clinical and economic impact of treatment decisions. Participants will leave with practical, evidence-based strategies to optimize patient outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Michigan Board of Pharmacy
Pharmacist
Pharmacist Special Volunteer
New Hampshire Board of Pharmacy
Pharmacist
Disclosure statements
The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose:
Leslie Citrome, who participated as a planner-reviewer and speaker, has served as a consultant for AbbVie, Acadia, AdhereTech, Altus, Alumis, Axsome, Alkermes, Arc, Auritec, Autobahn, Avant Healthcare Solutions, Biogen, BioXcel, BMS/Karuna, Boehringer Ingelheim, Cadent, Cerevel, Clario/MedAvante/ProPhase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health & Wellness Partners, HLS, Idorsia, Inmune Bio, Intra-Cellular, Johnson & Johnson/Janssen, Little Bear, Lundbeck, Luye, Lyndra, MapLight, Marvin, MindMed, Neurelis, Neushen, Neumora, Neurocrine, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo/Sunovion, Supernus, Teva, and Vanda. He has served as a speaker for AbbVie, Acadia, Alkermes, BMS, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, and Vanda. He holds stock options in Reviva, a public company, and has received royalties or publishing income from Taylor & Francis as Editor-in-Chief of Current Medical Research and Opinion (2022–present), Springer Healthcare for a book, and Elsevier as Topic Editor for Psychiatry in Clinical Therapeutics through spring 2025.
Mark Garofoli, who participated as a planner-reviewer and speaker, has served as a consultant for Tris Pharma, Yaral Pharma, and Kenvue.
April Kraft, who participated as a speaker, has served as a patient ambassador for Neurocrine Biosciences.
These individuals have or have had within the last 24 months financial relationships with one or more ineligible companies. These relationships have been mitigated by PeerPoint Medical Education Institute and Real World CE.
All other presenters, planners, editors, and staff report no current financial relationships, or financial relationships within the last 24 months, with ineligible companies.
This activity may include discussion of investigational or off-label uses of products or devices. PeerPoint Medical Education Institute and AchieveCE does not endorse or promote the use of any product or device outside its approved indications.
Artificial Intelligence (AI) Disclaimer Statement
Consistent with guidance from the Accreditation Council for Continuing Medical Education (ACCME), any individuals in control of content must disclose if artificial intelligence (AI) was used in the development of this educational activity. Such disclosure should include the name of the AI tool(s) utilized and the extent of its role in content creation.
PeerPoint and AchieveCE reviews all educational materials to ensure they are evidence-based, balanced, and compliant with ACCME Standards for Integrity and Independence, including the identification and mitigation of any potential biases.
AI technologies may be used to support content development; however, they are not a substitute for clinical expertise. Learners are encouraged to apply independent clinical judgment and critically assess the information presented when making decisions relat